Combination of Capecitabine and GTI-2040 in the Treatment of Renal Cell Carcinoma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

December 31, 2004

Conditions
Carcinoma, Renal CellMetastases, Neoplasm
Interventions
DRUG

GTI-2040

Trial Locations (10)

13210

SUNY Upstate Medical University, Syracuse

19111

Fox Chase Cancer Center, Philadelphia

33138

Innovative Medical Research of South Florida, Inc., Miami Shores

44195

The Cleveland Clinic Foundation, Cleveland

60637

University of Chicago Medical Center, Chicago

70121

Ochsner Clinic Foundation, New Orleans

90033

USC-Norris Comprehensive Cancer Center and Hospital, Los Angeles

90505

CA Hematology Oncology Medical Group, Torrance

94520

Bay Area Cancer Research Group, Concord

27157-1082

Comprehensive Cancer Center of Wake Forest University, Winston-Salem

Sponsors
All Listed Sponsors
collaborator

Wake Forest University

OTHER

collaborator

University of Chicago

OTHER

lead

Aptose Biosciences Inc.

INDUSTRY